How do you justify adjuvant radiotherapy in pancreatic cancer?
I can't convince the surgeons to refer their patients for adjuvant RT because the prospective data is messy and doesn’t seem to indicate a benefit. The best median survival in the retrospective studies is similar to that in the prospective chemotherapy alone studies (20-23 months).
2 Answers
Mednet MemberInvited Expert
Radiation Oncology · Memorial Sloan-Kettering Cancer Center
Answered on · Updated on
Even though it was flawed in every imaginal way, ESPAC1 had a high impact and made post-op chemoradiation experimental. Prior to that, radiation was not based on very much evidence. GITSG was a 40-patient positive study; the EORTC trial was negative. After the ESPAC1, the focus shifted to neoadjuvan...
Join for free or sign in to see the full answer
Mednet MemberInvited Expert
Radiation Oncology · Brigham and Women's Hospital
Answered on
In terms of randomized data, the only positive trial is GITSG. This is so small, accrued over such a long time, and was done such a long time ago, that it cannot be considered compelling evidence for treatment. The EORTC trial had similar results to GITSG, but the results did not reach statistical s...
Join for free or sign in to see the full answer